Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD. Whilst brain neurodegenerative processes play a part in the pathogenesis of these fluctuations, a range of barriers across the gastrointestinal (GI) tract can alter levodopa pharmacokinetics, ultimately contributing to non‐optimal levodopa response and symptoms fluctuations. GI barriers to levodopa transport and absorption include dysphagia, delayed gastric emptying, constipation, Helicobacter pylori infection, small intestinal bacterial overgrowth and gut dysbiosis. In addition, a protein‐rich diet and concomitant medication intake can further alter levodopa pharmacokinetics. This can result in unpredictable or sub‐optimal levodopa response, ‘delayed on’ or ‘no on’ phenomena. In this narrative review, we provided an overview on the plethora of GI obstacles to levodopa transport and absorption in PD and their implications on levodopa pharmacokinetics and development of motor fluctuations. In addition, management strategies to address GI dysfunction in PD are highlighted, including use of non‐oral therapies to bypass the GI tract.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diatchenko, L., Slade, G. D., Nackley, A. G., Bhalang, K., Sigurdsson, A., Belfer, I., Goldman, D., Xu, K., Shabalina, S. A., Shagin, D., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi013 · Cited by 1,280
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Chaudhuri, K. R., Martinez‐Martin, P., Schapira, A. H. V., Stocchi, F., Sethi, K., Odin, P., Brown, R. G., Koller, W., Barone, P., MacPhee, G., et al. (2006) · Movement Disorders · doi:10.1002/mds.20844 · Cited by 1,100 · cited 1×
“Constipation has a prevalence of 20%– 89% [3,34,90] and is up to sixfold more common amongst PwP than amongst age- and sexmatched controls [90,91].”
BackgroundSelf-citationFrequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · cited 2×
“However, several studies have shown no changes in levodopa pharmacokinetic measurements after eradicating SIBO, suggesting that the underlying mechanism is probably multifactorial and highlighting the need for further research on the topic [82,88,89].”
Backgroundvan Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521 · cited 3×
“Another study showed that in the small intestine of rats receiving oral levodopa/carbidopa, levodopa plasma levels were negatively associated with the abundance of bacterial TDC gene [19].”
BackgroundMeta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370
The role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344 · cited 2×
“However, several studies have shown no changes in levodopa pharmacokinetic measurements after eradicating SIBO, suggesting that the underlying mechanism is probably multifactorial and highlighting the need for further research on the topic [82,88,89].”
BackgroundCersosimo, M. G., Raina, G. B., Pecci, C., Pellene, A., Calandra, C. R., Gutiérrez, C., Micheli, F. E., & Benarroch, E. E. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6801-2 · Cited by 314
Small intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274 · cited 2×
“Small intestinal bacterial overgrowth has been associated with increased frequency of motor fluctuations, longer ‘off’ phases and suboptimal response to levodopa, resulting in worse motor function overall [86,87].”
Background
Cited by
Liu, J., Chen, Q., & Su, R. (2024) · Medicine · doi:10.1097/md.0000000000037960 · Cited by 25
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Metadata
- Authors
- Leta, V., Klingelhoefer, L., Longardner, K., Campagnolo, M., Levent, H. Ç., Aureli, F., Metta, V., Bhidayasiri, R., Chung‐Faye, G., Falup‐Pecurariu, C., Stocchi, F., Jenner, P., Warnecke, T., Ray Chaudhuri, K., & International Parkinson and Movement Disorders Society Non‐Motor Parkinson's Disease Study Group
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2023-03-07
- Volume
- 30
- Issue
- 5
- Pages
- 1465-1480
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W4319657115
- Cited by
- 126
- References
- 19
- FWCI
- 18.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. https://app.cochat.ai/papers/10.1111/ene.15734
- The paper
- Leta, V., Klingelhoefer, L., Longardner, K., Campagnolo, M., Levent, H. Ç., Aureli, F., Metta, V., Bhidayasiri, R., Chung‐Faye, G., Falup‐Pecurariu, C., Stocchi, F., Jenner, P., Warnecke, T., Ray Chaudhuri, K., & International Parkinson and Movement Disorders Society Non‐Motor Parkinson's Disease Study Group. (2023). Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. European Journal of Neurology. https://doi.org/10.1111/ene.15734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.